Cargando…
Enhanced transdermal delivery of lornoxicam by nanostructured lipid carrier gels modified with polyarginine peptide for treatment of carrageenan-induced rat paw edema
Background: Nanostructured lipid carriers (NLCs) are emerging as attractive drug carriers in transdermal drug delivery. The surface modification of NLCs with cell-penetrating peptides (CPPs) can enhance the skin permeation of drugs. Purpose: The objective of the current study was to evaluate the abi...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Dove
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683961/ https://www.ncbi.nlm.nih.gov/pubmed/31447556 http://dx.doi.org/10.2147/IJN.S205295 |
_version_ | 1783442193514496000 |
---|---|
author | Gao, Shanshan Tian, Baocheng Han, Jingtian Zhang, Jing Shi, Yanan Lv, Qingzhi Li, Keke |
author_facet | Gao, Shanshan Tian, Baocheng Han, Jingtian Zhang, Jing Shi, Yanan Lv, Qingzhi Li, Keke |
author_sort | Gao, Shanshan |
collection | PubMed |
description | Background: Nanostructured lipid carriers (NLCs) are emerging as attractive drug carriers in transdermal drug delivery. The surface modification of NLCs with cell-penetrating peptides (CPPs) can enhance the skin permeation of drugs. Purpose: The objective of the current study was to evaluate the ability of the cell-penetrating peptide (CPP) polyarginine to translocate NLCs loaded with lornoxicam (LN) into the skin layers and to evaluate its anti-inflammatory effect. Methods: The NLCs were prepared using an emulsion evaporation and low temperature solidification technique using glyceryl monostearates, triglycerides, DOGS-NTA-Ni lipids and surfactants, and then six histidine-tagged polyarginine containing 11 arginine (R11) peptides was modified on the surface of NLCs. Results: The developed NLCs formulated with LN and R11 (LN-NLC-R11) were incorporated into 2% HPMC gels. NLCs were prepared with a particle size of (121.81±3.61)–(145.72±4.78) nm, and the zeta potential decreased from (−30.30±2.07) to (−14.66±0.74) mV after the modification of R11 peptides. The encapsulation efficiency and drug loading were (74.61±1.13) % and (7.92±0.33) %, respectively, regardless of the surface modification. Cellular uptake assays using HaCaT cells suggested that the NLC modified with R11 (0.02%, w/w) significantly enhanced the cell internalization of nanoparticles relative to unmodified NLCs (P<0.05 or P<0.01). An in vitro skin permeation study showed better permeation-enhancing ability of R11 (0.02%, w/w) than that of other content (0.01% or 0.04%). In carrageenan-induced rat paw edema models, LN-NLC-R11 gels inhibited rat paw edema and the production of inflammatory cytokines compared with LN-NLC gels and LN gels (P<0.01). Conclusion: In our investigation, it was strongly demonstrated that the surface modification of NLC with R11 enhanced the translocation of LN across the skin, thereby alleviating inflammation. |
format | Online Article Text |
id | pubmed-6683961 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Dove |
record_format | MEDLINE/PubMed |
spelling | pubmed-66839612019-08-23 Enhanced transdermal delivery of lornoxicam by nanostructured lipid carrier gels modified with polyarginine peptide for treatment of carrageenan-induced rat paw edema Gao, Shanshan Tian, Baocheng Han, Jingtian Zhang, Jing Shi, Yanan Lv, Qingzhi Li, Keke Int J Nanomedicine Original Research Background: Nanostructured lipid carriers (NLCs) are emerging as attractive drug carriers in transdermal drug delivery. The surface modification of NLCs with cell-penetrating peptides (CPPs) can enhance the skin permeation of drugs. Purpose: The objective of the current study was to evaluate the ability of the cell-penetrating peptide (CPP) polyarginine to translocate NLCs loaded with lornoxicam (LN) into the skin layers and to evaluate its anti-inflammatory effect. Methods: The NLCs were prepared using an emulsion evaporation and low temperature solidification technique using glyceryl monostearates, triglycerides, DOGS-NTA-Ni lipids and surfactants, and then six histidine-tagged polyarginine containing 11 arginine (R11) peptides was modified on the surface of NLCs. Results: The developed NLCs formulated with LN and R11 (LN-NLC-R11) were incorporated into 2% HPMC gels. NLCs were prepared with a particle size of (121.81±3.61)–(145.72±4.78) nm, and the zeta potential decreased from (−30.30±2.07) to (−14.66±0.74) mV after the modification of R11 peptides. The encapsulation efficiency and drug loading were (74.61±1.13) % and (7.92±0.33) %, respectively, regardless of the surface modification. Cellular uptake assays using HaCaT cells suggested that the NLC modified with R11 (0.02%, w/w) significantly enhanced the cell internalization of nanoparticles relative to unmodified NLCs (P<0.05 or P<0.01). An in vitro skin permeation study showed better permeation-enhancing ability of R11 (0.02%, w/w) than that of other content (0.01% or 0.04%). In carrageenan-induced rat paw edema models, LN-NLC-R11 gels inhibited rat paw edema and the production of inflammatory cytokines compared with LN-NLC gels and LN gels (P<0.01). Conclusion: In our investigation, it was strongly demonstrated that the surface modification of NLC with R11 enhanced the translocation of LN across the skin, thereby alleviating inflammation. Dove 2019-08-02 /pmc/articles/PMC6683961/ /pubmed/31447556 http://dx.doi.org/10.2147/IJN.S205295 Text en © 2019 Gao et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php). |
spellingShingle | Original Research Gao, Shanshan Tian, Baocheng Han, Jingtian Zhang, Jing Shi, Yanan Lv, Qingzhi Li, Keke Enhanced transdermal delivery of lornoxicam by nanostructured lipid carrier gels modified with polyarginine peptide for treatment of carrageenan-induced rat paw edema |
title | Enhanced transdermal delivery of lornoxicam by nanostructured lipid carrier gels modified with polyarginine peptide for treatment of carrageenan-induced rat paw edema |
title_full | Enhanced transdermal delivery of lornoxicam by nanostructured lipid carrier gels modified with polyarginine peptide for treatment of carrageenan-induced rat paw edema |
title_fullStr | Enhanced transdermal delivery of lornoxicam by nanostructured lipid carrier gels modified with polyarginine peptide for treatment of carrageenan-induced rat paw edema |
title_full_unstemmed | Enhanced transdermal delivery of lornoxicam by nanostructured lipid carrier gels modified with polyarginine peptide for treatment of carrageenan-induced rat paw edema |
title_short | Enhanced transdermal delivery of lornoxicam by nanostructured lipid carrier gels modified with polyarginine peptide for treatment of carrageenan-induced rat paw edema |
title_sort | enhanced transdermal delivery of lornoxicam by nanostructured lipid carrier gels modified with polyarginine peptide for treatment of carrageenan-induced rat paw edema |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6683961/ https://www.ncbi.nlm.nih.gov/pubmed/31447556 http://dx.doi.org/10.2147/IJN.S205295 |
work_keys_str_mv | AT gaoshanshan enhancedtransdermaldeliveryoflornoxicambynanostructuredlipidcarriergelsmodifiedwithpolyargininepeptidefortreatmentofcarrageenaninducedratpawedema AT tianbaocheng enhancedtransdermaldeliveryoflornoxicambynanostructuredlipidcarriergelsmodifiedwithpolyargininepeptidefortreatmentofcarrageenaninducedratpawedema AT hanjingtian enhancedtransdermaldeliveryoflornoxicambynanostructuredlipidcarriergelsmodifiedwithpolyargininepeptidefortreatmentofcarrageenaninducedratpawedema AT zhangjing enhancedtransdermaldeliveryoflornoxicambynanostructuredlipidcarriergelsmodifiedwithpolyargininepeptidefortreatmentofcarrageenaninducedratpawedema AT shiyanan enhancedtransdermaldeliveryoflornoxicambynanostructuredlipidcarriergelsmodifiedwithpolyargininepeptidefortreatmentofcarrageenaninducedratpawedema AT lvqingzhi enhancedtransdermaldeliveryoflornoxicambynanostructuredlipidcarriergelsmodifiedwithpolyargininepeptidefortreatmentofcarrageenaninducedratpawedema AT likeke enhancedtransdermaldeliveryoflornoxicambynanostructuredlipidcarriergelsmodifiedwithpolyargininepeptidefortreatmentofcarrageenaninducedratpawedema |